Avelumab (Bavencio?) is a fully human anti-PD-L1 IgG1 lambda monoclonal antibody that has a molecular weight of approximately 147 kDa. Avelumab binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7-1. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. By retaining anative Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity. Importantly, avelumab has not shown antibody-dependent cellmediated cytotoxicity against immune cell subsets in humans. BioSim? Avelumab ELISA kit has been developed for specific quantification of Avelumab concentration in human serum or plasma with high sensitivity and reproducibility.
產(chǎn)品特點(diǎn)
Easy, convenient, sensitive and time-saving method to measure the level of Avelumab in human serum and plasma.
Detection Range: 100 - 3000 ng/ml
Sensitivity: 30 ng/ml
Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
Cross Reactivity: No significant cross-reactivity or interference with other proteins present in native human serum or other therapeutic immunoglobulins.
Recovery rate: 85 – 115% with normal human serum samples with known concentrations